Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Eligible age
18+ yrs
Accepts
All genders
Locations
36 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer returning (low risk recurrence). Ribociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hormone therapy, with letrozole, anastrozole or exemestane, lowers the amount of estrogen made by the body. This may help stop the growth of tumor cells that need estrogen to grow. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Hormone therapy plus ribociclib may work as well as chemotherapy followed by hormone therapy plus ribociclib for the treatment of high anatomic stage breast cancer with low recurrence risk.
Sponsor: National Cancer Institute (NCI)
You may qualify if…
- ✓ STEP 0: Patient must be ≥ 18 years of age
- ✓ STEP 0: Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 28 days prior to Step 0 pre-registration
- ✓ STEP 0: Patient must be a postmenopausal woman or a man
- ✓ NOTE: Menopause can be determined by any of the following:
- ✓ Prior bilateral oophorectomy
- ✓ Age ≥ 60 years
- ✓ Age \< 60 years with amenorrhea for ≥ 12 months and estradiol and follicle stimulating hormone (FSH) levels in the postmenopausal range
- ✓ NOTE: FSH and estradiol levels should be repeated as clinically indicated to ensure menopausal status in patients with breast cancer with chemotherapy-induced amenorrhea
Where it's recruiting
Jonesboro
Auburn · Berkeley · Beverly Hills · Fremont …
Westminster
Stamford
Millville · Newark · Rehoboth Beach
Lakeland
Coeur d'Alene · Post Falls · Sandpoint
Bloomington · Canton · Carterville · Carthage …
Avon · Carmel · Indianapolis
Ames · Ankeny · Carroll · Cedar Rapids …
Hays · Kansas City · Olathe · Overland Park …
New Orleans
Source: ClinicalTrials.gov · NCT07391774 · last updated 2026-11-20